Actuate Therapeutics (ACTU) investor relations material

Company overview and business model

• Clinical-stage biopharmaceutical developer focused on difficult-to-treat cancers through elraglusib, an ATP-competitive small-molecule GSK-3β inhibitor exclusively licensed from the University of Illinois Chicago and Northwestern University.

• Elraglusib is positioned as a potential multi-indication asset; areas under evaluation include pancreatic, melanoma, lung, colorectal, breast, renal and ovarian cancers, blood cancers and selected pediatric cancers.

• More than 500 patients have received IV elraglusib in Phase 1 and Phase 2 studies; an oral tablet received FDA clearance to proceed in a Phase 1/2 study, subject to additional funding.

• Oral-tablet development plans include dose finding in adults with advanced refractory cancers, followed by potential Phase 2 or registrational studies in metastatic pancreatic, melanoma, colorectal and non-small cell lung cancers.

• Pediatric IV development identified Ewing sarcoma and neuroblastoma as potential indications; a planned BEACON2 dose-confirmation cohort may enroll up to 20 patients, subject to funding.

Financial performance and metrics

• No product-sales revenue since inception; significant operating losses and negative operating cash flows, with significant future expenses expected as clinical development advances.

• At June 30, 2026, cash and cash equivalents were $4,425,841 and working capital was $942,745; net tangible book value was ~$0.99 million, or ~$0.04 per share.

• At the assumed $0.50 per-share offering price, adjusted net tangible book value would be ~$0.30 per share; immediate dilution to new investors is ~$0.20 per share.

• Since March 2025, 539,967 shares were sold under the B. Riley committed equity facility for net proceeds of $3,800,465; remaining capacity was 3,364,407 shares at June 30, 2026.

Use of proceeds and capital allocation

• Net proceeds are intended for working capital and general corporate purposes; no specific amounts or allocations are set, leaving management broad discretion over timing and use.

• Continued clinical development, including the oral-tablet program, is subject to additional funding; further financing may come from equity, debt, collaborations, licenses or similar arrangements.